阿尔茨海默病中的免疫细胞:对病原体和潜在治疗点的洞察
Xiaofeng Fu1, Huimin Cai1, Shuiyue Quan1
1Innovation Center for Neurological Disorders and Department of Neurology, Xuanwu Hospital, Capital Medical University, National Clinical Research Center for Geriatric Diseases, Beijing, China.
Medical review (2021)
|July 2, 2025
概括
阿尔茨海默病涉及免疫系统,大脑和血液免疫细胞驱动神经炎症. 了解这些作用对于开发这种神经退行性疾病的新疗法至关重要.
科学领域:
- 神经免疫学 神经免疫学
- 神经炎症是一种神经炎症.
- 阿尔茨海默氏症疾病的发病因子
背景情况:
- 阿尔茨海默病 (AD) 越来越多地被认为是一种与免疫系统功能障碍相关的系统性疾病,扩展到中枢神经系统 (CNS) 以外.
- 免疫细胞,包括微质细胞,星体细胞,T细胞,B细胞和单细胞/巨细胞,在AD的启动和进展中起着至关重要的作用.
- 神经炎症是阿尔茨海默氏症发病的一个核心组成部分,受常驻大脑免疫细胞和透到外围免疫细胞的影响.
研究的目的:
- 审查中央和外围免疫细胞在阿尔茨海默病相关的神经炎症中的多方面的作用.
- 在AD的背景下,探索中央和外周免疫系统之间的复杂相互作用.
- 突出正在进行的针对神经炎症的临床试验作为AD的治疗策略.
主要方法:
- 综合文献综述,重点关注阿尔茨海默病的免疫学方面.
- 在AD病变发生过程中分析了微质细胞,星体细胞和外周免疫细胞的功能.
- 对针对AD相关神经炎症的治疗方法的临床试验数据的检查.
主要成果:
- 中枢先天性免疫细胞 (微细胞,星体细胞) 和外围免疫细胞 (T细胞,B细胞,单细胞/巨细胞,中性粒细胞) 显著促进AD神经炎症.
- 中枢神经系统和外围免疫细胞之间的复杂相互作用调节了疾病的进展.
- 针对神经炎症的临床试验显示了未来AD治疗方法的前景.
结论:
- 免疫细胞的参与对阿尔茨海默病的发病过程至关重要,突出显示了该疾病的系统性质.
- 针对神经炎症是阿尔茨海默病的有希望的治疗途径.
- 对免疫细胞动态的进一步研究对于开发有效的AD治疗是至关重要的.
相关概念视频
Alzheimer's Disease: Overview
678
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
678
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265


